Next-generation drugs inclusion to the South's HIV/AIDS programs: The Brazilian experience on third-line drugs - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of the International AIDS Society Année : 2013

Next-generation drugs inclusion to the South's HIV/AIDS programs: The Brazilian experience on third-line drugs

(1) , (1) , (2)
1
2

Résumé

Brazil, which has one of the largest patients cohort (315 000 people on TARV) and one of the oldest, is the first country in the south to confront the challenge of third-line treatments distribution. Currently, the National Program HIV/AIDS distributes six third-line ARV (Darunavir, enfuvirtide, étravirine, raltégravir, tipranavir and maraviroc) to the patients in virological treatment failure. Our research is interested in the evolution of the purchase price of each ARV and the impact of third-lines on the total budget devoted to acquisition of ARVs.
Fichier principal
Vignette du fichier
Abstract HIV ZAIRE hal.pdf (361.58 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-01493257 , version 1 (21-03-2017)

Identifiants

Citer

Carla Zaire, Benjamin Coriat, Lia Hansenclever. Next-generation drugs inclusion to the South's HIV/AIDS programs: The Brazilian experience on third-line drugs. Journal of the International AIDS Society, 2013, 16 (1), ⟨10.7448/IAS.16.2.18685⟩. ⟨hal-01493257⟩
58 Consultations
143 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More